Literature DB >> 22633796

Impact of body mass index and waist circumference on the cardiovascular risk and all-cause death in a general population: data from the PAMELA study.

M Bombelli1, R Facchetti, D Fodri, G Brambilla, R Sega, G Grassi, G Mancia.   

Abstract

BACKGROUND AND AIMS: Elevated values of body mass index (BMI) and waist circumference (WC) are associated with an augmented cardiovascular (CV) risk. It is debated, however, whether and to what extent this depends on the body fat increase 'per se' or on the related cardiometabolic alterations. METHODS AND
RESULTS: In 2005 subjects randomly selected from the general population of Monza (Italy), we assessed BMI, WC, office, home and 24 h blood pressure (BP), heart rate and metabolic variables. The impact of BMI and WC on the incidence of CV events, CV and all-cause mortality was estimated during a 148-month follow-up. Progressively higher values of BMI and WC were associated with a progressive increase in office, home and 24 h BP and in erratic BP variability (P < 0.0001 for trend). Metabolic variables were directly and significantly (P < 0.0001) related to BMI and WC, while an inverse significant relationship was detected with high-density lipoprotein (HDL)-cholesterol. The incidence of CV events, CV and all-cause deaths increased progressively from the lowest to the highest quintile of BMI and WC (P for trend always <0.005). Baseline BMI and WC higher by respectively 1 kg m⁻² and 1 cm were associated with an increased risk of CV events, CV and all-cause death by 8%, 12% and 7% (for baseline BMI) and 4%, 5% and 4% (for baseline WC), respectively. After adjustment for confounders, only the increased risk of CV death related to higher baseline BMI remained significant (hazard ratio (HR) 1.062, confidence interval (CI) 95% 1.003-1.126, P < 0.05).
CONCLUSION: The adverse prognostic impact of the accumulation of body fat is mediated by the associated haemodynamic and metabolic alterations. Baseline values of BMI, however, are an independent predictor of CV mortality.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22633796     DOI: 10.1016/j.numecd.2012.01.004

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  10 in total

Review 1.  Obesity and heart failure as a mediator of the cerebrorenal interaction.

Authors:  Ankur Jindal; Adam Whaley-Connell; James R Sowers
Journal:  Contrib Nephrol       Date:  2013-05-03       Impact factor: 1.580

2.  A new predictive equation for evaluating women body fat percentage and obesity-related cardiovascular disease risk.

Authors:  A De Lorenzo; A Nardi; L Iacopino; E Domino; G Murdolo; C Gavrila; D Minella; G Scapagnini; L Di Renzo
Journal:  J Endocrinol Invest       Date:  2014-01-24       Impact factor: 4.256

3.  Obesity and the Cardiorenal Metabolic Syndrome: Therapeutic Modalities and Their Efficacy in Improving Cardiovascular and Renal Risk Factors.

Authors:  Ankur Jindal; Stephen Brietzke; James R Sowers
Journal:  Cardiorenal Med       Date:  2012-11-24       Impact factor: 2.041

Review 4.  The Pamela study: main findings and perspectives.

Authors:  Michele Bombelli; Elena Toso; Maria Peronio; Danilo Fodri; Marco Volpe; Gianmaria Brambilla; Rita Facchetti; Roberto Sega; Guido Grassi; Giuseppe Mancia
Journal:  Curr Hypertens Rep       Date:  2013-06       Impact factor: 5.369

Review 5.  New obesity classification criteria as a tool for bariatric surgery indication.

Authors:  Antonino De Lorenzo; Laura Soldati; Francesca Sarlo; Menotti Calvani; Nicola Di Lorenzo; Laura Di Renzo
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

6.  Effects on office and home blood pressure of the lercanidipine-enalapril combination in patients with Stage 2 hypertension: a European randomized, controlled clinical trial.

Authors:  Giuseppe Mancia; Antonio Coca; Irina Chazova; Xavier Girerd; Hermann Haller; Paolo Pauletto; Danuta Pupek-Musialik; Yevgeniya Svyshchenko
Journal:  J Hypertens       Date:  2014-08       Impact factor: 4.844

7.  Alpha-Adrenergic Mechanisms in the Cardiovascular Hyperreactivity to Norepinephrine-Infusion in Essential Hypertension.

Authors:  Lisa-Marie Walther; Roland von Känel; Nadja Heimgartner; Claudia Zuccarella-Hackl; Guido Stirnimann; Petra H Wirtz
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-22       Impact factor: 6.055

Review 8.  Obesity and surgical wound healing: a current review.

Authors:  Yvonne N Pierpont; Trish Phuong Dinh; R Emerick Salas; Erika L Johnson; Terry G Wright; Martin C Robson; Wyatt G Payne
Journal:  ISRN Obes       Date:  2014-02-20

9.  Anthropometric trends and the risk of cardiovascular disease mortality in a Lithuanian urban population aged 45-64 years.

Authors:  Dalia Luksiene; Abdonas Tamosiunas; Dalia Virviciute; Gailute Bernotiene; Anne Peasey
Journal:  Scand J Public Health       Date:  2015-08-10       Impact factor: 3.021

10.  Associations of the lipid genetic variants Thr54 ( FABP2) and -493T ( MTTP) with total cholesterol and low-density lipoprotein cholesterol levels in Mexican subjects.

Authors:  Karina Gonzalez-Becerra; Omar Ramos-Lopez; Mary Lolis Garcia-Cazarin; Elisa Barron-Cabrera; Arturo Panduro; Erika Martinez-Lopez
Journal:  J Int Med Res       Date:  2018-01-17       Impact factor: 1.671

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.